It integrates traditional risk factors—blood pressure, lipid profiles, smoking status, diabetes—with female-specific variables such as adverse pregnancy outcomes, menopausal status, and circulating sex hormone levels.
- Enhanced predictive accuracy for midlife women through integration of female‐specific factors (adverse pregnancy outcomes, menopause status, sex hormone levels) alongside traditional CVD risk factors.
By incorporating reproductive health data alongside conventional metrics, the model captures risk signals unique to midlife women.
University of Pittsburgh researchers have developed a novel therapy for chondrocyte aging and, ultimately, osteoarthritis (OA).
Recognizing substance use during pregnancy can lead to harm reduction interventions, improving pregnancy outcomes and child health.
SBIRT and Obstetrics has been specifically tailored to healthcare professionals (HCPs) working in primary care settings to arm them with the ability to screen for substance use and provide education to address this issue in pregnancy.
A University of Pittsburgh research group, Pharmacy Evaluation and Research Unit (PERU), has developed a novel educational tool, SBIRT (Screening, Brief Intervention, Referral to Treatment) and Obstetrics.
Additionally, use during pregnancy increases the likelihood of adverse birth outcomes.
University of Pittsburgh researchers have engineered a next-generation soluble CD4-D1 domain with enhanced stability and extended in vivo half-life, designed to serve as a potent HIV entry inhibitor.
In recent years, HPV vaccines and pap smears have reduced the rates of genital HPV+ cancers.
• Other HPV+ oropharyngeal cancers.
This liquid biopsy could be assessed for biomarkers of HPV+ cancers including analysis of cfDNA using NGS techniques.
Engineered monoclonal antibodies have been developed to target specific regions of a TAT-C1aB fusion peptide with high precision.
This invention is a mobile application for Android and iOS that supports maternal and infant health during the first year after birth.
Extirpative surgeries, radiation treatment, congenital anomalies, ovariectomy, menopause, aging, chemotherapy, and vaginal birth trauma can all result in loss or impairment of vaginal structure and function.
Extirpative surgeries, radiation treatment, congenital anomalies, ovariectomy, menopause, aging, chemotherapy, and vaginal birth trauma can all result in loss or impairment of vaginal structure and function.
Researchers at Pitt developed a novel hydrogel biofabricated from porcine vaginal extracellular matrix (vECM) and its potential applications in the field of Urogynecology.
University of Pittsburgh researchers have identified a novel extracellular protein domain in hepatocellular carcinoma (HCC) and developed a monoclonal antibody (mAb) to recognize this target.
· Brain cancer. · Ovarian cancers. · Breast cancers. · Pediatric medulloblastoma.
Investigation of the presence of antibodies against Zika prior and during pregnancy is very important to implement infection prevention measures and to determine the viral infection of the mother.
Through Pan-Cancer Analysis of Whole Genomes, it has been found that IGR burden is a pivotal contributor to increased T-inflamed signature in selected tumor entities such as breast cancer, ovarian cancer, uterine corpus endometrial cancer, and esophageal adenocarcinoma, and correlates with increased type-I immune response effectors, such as Macrophage M1 and CD8+ T cells.
University of Pittsburgh researchers have developed EndoDx, a groundbreaking diagnostic tool that leverages machine learning to diagnose endometriosis (EM) early and non-invasively.
This model predicts the presence and severity of endometriosis, offering a non-invasive alternative to surgical diagnosis.
• Diagnostic tool for endometriosis.
Established in a controlled laboratory environment with rigorous consent protocols, it has been meticulously developed to serve as an effective in vitro platform for studying breast cancer biology and therapeutic responses.
This tool has gained recognition in prominent scientific forums and is being shared with the broader research community through established agreements, enhancing collaborative efforts to advance treatment strategies for breast cancer.
- Addresses a critical gap in available breast cancer research models, particularly for ER-negative ILC.